Avalo Therapeutics, Inc. financial data

Symbol
AVTX on Nasdaq
Location
Wayne, PA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 06 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1660% % 1977%
Debt-to-equity 20% %
Return On Equity -88% % -372%
Return On Assets -74% % -716%
Operating Margin -15536% % -993%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 18,133,968 shares 74%
Common Stock, Shares, Outstanding 17,827,635 shares 84%
Entity Public Float $12,900,000 USD 169%
Common Stock, Value, Issued $18,000 USD 80%
Weighted Average Number of Shares Outstanding, Basic 14,000,451 shares 152%
Weighted Average Number of Shares Outstanding, Diluted 14,000,451 shares 30%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $0 USD -100%
General and Administrative Expense $21,599,000 USD 47%
Costs and Expenses $66,684,000 USD 4.7%
Operating Income (Loss) $66,492,000 USD -5.8%
Nonoperating Income (Expense) $33,237,000 USD -161%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $99,729,000 USD -1152%
Income Tax Expense (Benefit) $149,000 USD
Net Income (Loss) Attributable to Parent $99,878,000 USD -1155%
Earnings Per Share, Basic 122 USD/shares 0.51%
Earnings Per Share, Diluted 131 USD/shares 32%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $26,963,000 USD -67%
Cash, Cash Equivalents, and Short-term Investments $111,600,000 USD
Assets, Current $113,846,000 USD 32%
Operating Lease, Right-of-Use Asset $402,000 USD -65%
Goodwill $10,502,000 USD 0%
Assets $125,100,000 USD 27%
Accounts Payable, Current $474,000 USD -74%
Employee-related Liabilities, Current $3,381,000 USD 54%
Liabilities, Current $7,972,000 USD -87%
Deferred Income Tax Liabilities, Net $304,000 USD 97%
Operating Lease, Liability, Noncurrent $117,000 USD -89%
Other Liabilities, Noncurrent $117,000 USD -89%
Liabilities $33,553,000 USD -56%
Accumulated Other Comprehensive Income (Loss), Net of Tax $41,000 USD
Retained Earnings (Accumulated Deficit) $434,802,000 USD -30%
Stockholders' Equity Attributable to Parent $91,547,000 USD 334%
Liabilities and Equity $125,100,000 USD 27%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $9,457,000 USD -52%
Net Cash Provided by (Used in) Financing Activities $0 USD -100%
Net Cash Provided by (Used in) Investing Activities $0 USD -100%
Common Stock, Shares Authorized 200,000,000 shares 0%
Common Stock, Shares, Issued 17,827,635 shares 84%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $9,457,000 USD -109%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $27,263,000 USD -67%
Interest Paid, Excluding Capitalized Interest, Operating Activities $0 USD -100%
Deferred Tax Assets, Valuation Allowance $65,656,000 USD 15%
Deferred Tax Assets, Gross $65,386,000 USD 15%
Operating Lease, Liability $555,000 USD -66%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $30,550,000 USD -233%
Lessee, Operating Lease, Liability, to be Paid $595,000 USD -69%
Operating Lease, Liability, Current $438,000 USD -20%
Lessee, Operating Lease, Liability, to be Paid, Year Two $63,000 USD -89%
Lessee, Operating Lease, Liability, to be Paid, Year One $392,000 USD -29%
Deferred Income Tax Expense (Benefit) $8,000 USD 14%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $40,000 USD -87%
Lessee, Operating Lease, Liability, to be Paid, Year Three $0 USD -100%
Deferred Tax Assets, Operating Loss Carryforwards $42,689,000 USD 15%
Preferred Stock, Shares Authorized 5,000,000 shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four $0 USD -100%
Additional Paid in Capital $526,290,000 USD 48%
Depreciation, Depletion and Amortization $135,000 USD 297%
Share-based Payment Arrangement, Expense $12,016,000 USD 223%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%